Unknown PHASE4 INTERVENTIONAL 1-arm NCT05583240

Influence of Olfaction Essential Oils on the Consumption of Benzodiazepine Receptor Agonists & Z-Drugs (BZRAs) Prescribed as if Needed in Psychiatric Outpatients (HECBA-PSY). (HECBA-PSY)

Sponsor: Etablissement Public de Santé Barthélemy Durand

Conditions Benzodiazepine Withdrawal Psychiatric Disorder

Interventions Essences and Essential Oils

Updated 4 times since 2022 Last updated: Oct 15, 2022 Started: Apr 19, 2021 Primary completion: Apr 18, 2023 Completion: Jul 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Benzodiazepine Withdrawal and Psychiatric Disorder and is currently ongoing. Etablissement Public de Santé Barthélemy Durand leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

4 versions recorded

Nov 2024 — Present [monthly]

Unknown PHASE4

Status: Recruiting → Unknown
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4
Nov 2022 — Jul 2024 [monthly]

Recruiting PHASE4

First recorded

Apr 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Etablissement Public de Santé Barthélemy Durand

Data source: Etablissement Public de Santé Barthélemy Durand

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Étampes, France